Here's Why VCYT Stock Could be a Great Addition to Your Portfolio NowZacks Investment Research • 12/27/24
4 Healthcare Technology Innovators to Invest in Before the New YearZacks Investment Research • 12/19/24
Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025Zacks Investment Research • 12/16/24
Why Veracyte, With 55% Growth In 2024, Is An Outlier In Cancer DiagnosticsInvestors Business Daily • 12/12/24
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and InogenZacks Investment Research • 12/12/24
Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer GuidelinesBusiness Wire • 12/05/24
New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate CancerBusiness Wire • 09/15/24
3 Medical Instruments Industry Stocks to Buy on genAI and M&A BoostZacks Investment Research • 09/13/24
Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/05/24
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of DirectorsBusiness Wire • 09/04/24
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire • 08/26/24
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco ChronicleBusiness Wire • 08/26/24